拭目以待!查看全文
chuminhua2020-12-18 12:35
12/17,葛兰素史克(GSK)同意独家授权 Surface Oncology 的临床前NK细胞相关疗法SRF813的全球权利,交易价值可能超过8亿美元。这个靶向PVRIG的全人IgG1抗体的协议包括8500万美元的预付款,Surface Oncology也有资格获得高达7.3亿美元的额外里程碑和分级使用权费。
SRF813与PVRIG(一种在NK和T...查看全文
智通财经APP获悉,据媒体消息,专攻免疫疗法的Surface Oncology(SURF.US)公司收到了葛兰素史克(GSK.US)的收购意向。 报道称,除葛兰素史克之外,Surface Oncology还在寻找其它任何可能的收购者。 此前,百时美施贵宝(BMY.US)在同意收... 网页链接
$Surface Oncology(SURF)$ 15-12G Securities registration termination [Section 12(g)] Accession Number: 0001193125-23-236303 Act: 34 Size: 12 KB 网页链接
$Surface Oncology(SURF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002629 Act: 33 Size: 1 KB 网页链接
$Surface Oncology(SURF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002628 Act: 33 Size: 1 KB 网页链接
$Surface Oncology(SURF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-23-231522 Act: 33 Size: 21 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231530 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231534 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231535 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231539 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231542 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231544 Act: 33 Size: 23 KB 网页链接